Completed NA INTERVENTIONAL NCT00602342

Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions

A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 250 mg Terbinafine Hydrochloride Tablets Under Fasting Conditions

Sponsor: Roxane Laboratories

Conditions Onychomycosis

Interventions Terbinafine

Updated 7 times since 2017 Last updated: Jan 19, 2018 Started: Mar 31, 2004 Primary completion: Apr 30, 2004 Completion: Apr 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00602342, this NA trial focuses on Onychomycosis and remains completed. Sponsored by Roxane Laboratories, it has been updated 7 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed NA
Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 2 earlier versions

Feb 2018 — Jun 2018 [monthly]

Completed NA
Jan 2017 — Feb 2018 [monthly]

Completed NA

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Roxane Laboratories

Data source: West-Ward Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Saint Charles, United States